Amber Duncan, APRN
Family · Cross Lanes, WVNPI 1770964819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,625 of the $43,600 with a category attached, or 88.6%. AbbVie accounts for 96.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $16,313 and has fallen 73.0% since, to $4,397 in 2024. Among family clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $144.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- Lilly USA, LLC$450
- Boehringer Ingelheim$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$161
- Novo Nordisk$135
- Biohaven Pharmaceuticals, Inc.$128
- plus $480 from 12 others
What the payments were for
- Speaking & faculty fees$38,62589%
- Travel & lodging$8552%
- Food & beverage$4,1209%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 211 | $42,009 |
| Lilly USA, LLC | 27 | $450 |
| Boehringer Ingelheim | 12 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $161 |
| Novo Nordisk | 8 | $135 |
| Biohaven Pharmaceuticals, Inc. | 7 | $128 |
| Merck | 6 | $114 |
| Pfizer | 5 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| AstraZeneca | 3 | $55 |
| Amgen | 2 | $38 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 2 | $20 |
| Medline Industries LP | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,600 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $101,870 |
| OzempicSemaglutide | 36 | $51,923 |
| FarxigaDapagliflozin Propanediol | 54 | $46,817 |
| EliquisApixaban | 28 | $35,561 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $32,261 |
| JanuviaSitagliptin Phosphate | 14 | $22,235 |
| TrulicityDulaglutide | 20 | $20,834 |
| UbrelvyUbrogepant | 16 | $18,237 |
| MounjaroTirzepatide | 11 | $17,850 |
| RybelsusSemaglutide | 11 | $15,949 |
| Spiriva RespimatTiotropium Bromide | 19 | $13,434 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $12,323 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $10,107 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $6,670 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $5,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $237 | $115,30495 claims |
| Novo NordiskOzempic, Rybelsus | $135 | $67,87247 claims |
| AstraZenecaFarxiga, Symbicort | $55 | $59,13992 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $450 | $38,68431 claims |
| PfizerEliquis | $84 | $35,56128 claims |
| MerckJanuvia | $114 | $22,23514 claims |
| AbbVieUbrelvy, Synthroid | $42,009 | $20,59343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Cross Lanes
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
- Anne GharibHuntington$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.